Corneal Nerves After Treatment With Cenegermin

Neurotrophic Keratitis Clinical Trial

Official title: Structural and Functional Changes of Corneal Innervation After Treatment With Cenegermin

Status Recruiting

Clinical Trial Summary

Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in the cornea also result in damages of the cornea and in severe situation the loss of the eye. Cenegermin (trade name Oxervate) is a nerve growth factor eye drops designed to treat NK, and currently, it is the only FDA-approved medication for this purpose. Even though cenegermin is effective in the majority of patients, there is a lack of understanding of how cenegermin works in the eye. In this study, investigators aim to determine the structural and functional effects of cenegermin on the cornea, using non-invasive technologies including in vivo confocal microscopy on study participants with NK over the course of a year.

Clinical Trial Description

Cenegermin (OxervateTM) is a recombinant human form of nerve growth factor developed by Dompé Farmaceutici S.p.A. for patients who are diagnosed with corneal epithelial defects due to moderate to severe stages of NK. ;

Related Conditions & MeSH terms

• Keratitis
• Neurotrophic Keratitis

• NCT number: NCT04627571
• Study type: Observational
• Source: University of California, Los Angeles
• Contact: Simon Fung, MD
• Phone: 310-794-9581
• Email: simonfung@mednet.ucla.edu
• Status: Recruiting
• Start date: May 23, 2022
• Completion date: December 2024